SQA Validation and Qualification Flashcards

What is 'concurrent validation' and when is it typically used?

Answer: Validation performed during routine commercial production, used when limited batches are available due to rare products or urgent medical need

Concurrent validation collects validation data during actual commercial production and is acceptable in limited circumstances, such as for rare disease products, with appropriate risk justification.

What is the purpose of a Validation Summary Report?

Answer: To document all validation results, confirm acceptance criteria were met, and provide a conclusion about the validated state of the system or process

A Validation Summary Report consolidates all results, evaluates whether acceptance criteria were met, and documents the final conclusion and validation status.

What is Design Qualification (DQ) in equipment or system qualification?

Answer: Documented verification that the proposed design of a facility, equipment, or system is suitable for its intended purpose

DQ establishes that the design of the equipment or system meets user requirements and applicable regulatory requirements, before procurement or construction begins.

In analytical method validation, what does 'linearity' refer to?

Answer: The ability of a method to produce results directly proportional to the concentration of analyte within a defined range

Linearity demonstrates that the method response is directly proportional to analyte concentration over a specified range, typically assessed using the R² value from a calibration curve.

What is 'Continued Process Verification' (Stage 3 of FDA's process validation lifecycle)?

Answer: Ongoing monitoring of process performance during commercial manufacturing to ensure the process remains in a validated state

Stage 3 requires ongoing collection and statistical analysis of process data during commercial production to detect undesired variability and confirm the validated state is maintained.

What does a 'risk-based approach to validation' mean in pharmaceutical practice?

Answer: Directing validation effort toward systems and processes with the greatest potential impact on product quality and patient safety

A risk-based approach uses formal risk assessment tools (like FMEA) to prioritize validation resources for systems with the highest risk to product quality rather than applying equal effort everywhere.